A randomized and placebo-controlled double-blind, parallel-group study to investigate the cognitive efficacy of ascidian plasmalogens, - A randomized and placebo-controlled double-blind, parallel-group study to investigate the cognitive efficacy of ascidian plasmalogens,

Clinical Creative Corporation0 个研究点目标入组 146 人开始时间: 2020年8月18日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Persons taking medication for treatment of diseases (arrhythmia, liver damage, kidney damage, cerebrovascular disease, rheumatism, diabetes, dyslipidemia, hypertension and other chronic diseases) 2.Patients with malignancy, heart failure, or myocardial infarction, or who are undergoing treatment or have a history of such treatment 3.A person suffering from dementia 4.Those suffering from mental illnesses such as depression or attention deficit/hyperactivity disorder (ADHD) 5.Persons with allergies (pharmaceuticals and test foods) 6.Those who regularly consume foods or supplements that contribute to improving cognitive function, such as DHA, EPA, Ginkgo biloba extract, tocotrienol, astaxanthin, GABA, phosphatidylserine, lutein, zeaxanthin, imidazole dipeptides (carnosine, enserine, valenine), histidine, curcumin, bacopa saponin, lactonadecapeptide, anthocyanin, seryl tyrosine, auraptene, and diosgenin. 7.Persons who regularly consume pharmaceuticals (including herbal medicines), food for specified health uses, functional foods, or other foods/beverages with possible functional properties. 8.A person who has participated in another clinical trial within one month prior to obtaining consent or who is currently participating in another clinical trial. Those who, in the judgment of the principal investigator or sub-investigator, the conduct of the study may increase the risk to research subjects or may not provide sufficient data

发起方

Clinical Creative Corporation